Oct 2025 $4 M No. 6 $2 to $10 million 1
Elixirgen Therapeutics, Inc.: Raise no. 6, Oct 2025 × Investors in this round 1 investor had bought by the notice of Nov 13, 2025: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Akihiro Ko · Executive Officer, Director Hiroaki Kobayashi · Director Jeffrey Cleland · Director Minoru Ko · Director Shauna Callahan · Director Thomas White · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Akihiro Ko, Ceo. Source: SEC Form D, newest notice filed Nov 13, 2025. Read the notice at the SEC .
debt, options SEC Mar 2025 $4 M No. 5 $2 to $10 million 2
Elixirgen Therapeutics, Inc.: Raise no. 5, Mar 2025 × Investors in this round 2 investors had bought by the notice of Apr 9, 2025: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Akihiro Ko · Executive Officer, Director Hiroaki Kobayashi · Director Jeffrey Cleland · Director Minoru Ko · Director Shauna Callahan · Director Thomas White · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Akihiro Ko, Ceo. Source: SEC Form D, newest notice filed Apr 9, 2025. Read the notice at the SEC .
debt, options SEC Nov 2023 $7 M No. 4 $2 to $10 million 1
Elixirgen Therapeutics, Inc.: Raise no. 4, Nov 2023 × Investors in this round 1 investor had bought by the notice of Dec 1, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Akihiro C Ko · Executive Officer, Director Hiroaki C Kobayashi · Director Jeffrey K. Cleland · Director Minoru S.H. Ko · Director Shauna K. Callahan · Director Thomas K. White · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “This pertains to the issuance of Series A-3 Preferred Units, including the conversion of convertible securities”Signed by Akihiro Ko, Ceo. Source: SEC Form D, newest notice filed Dec 1, 2023. Read the notice at the SEC .
equity SEC Feb 2021 $4 M No. 3 $2 to $10 million 2
Elixirgen Therapeutics, Inc.: Raise no. 3, Feb 2021 × Investors in this round 2 investors had bought by the notice of Feb 18, 2021: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $6 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Akihiro Ko · Executive Officer, Director Hiroaki Kobayashi · Director Minoru Ko · Director Naonori Kurokawa · Director Shauna Callahan · Director Thomas White · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Akihiro Ko, CEO / Director. Source: SEC Form D, newest notice filed Feb 18, 2021. Read the notice at the SEC .
equity SEC Nov 2019 $6 M No. 2 $2 to $10 million 3
Elixirgen Therapeutics, Inc.: Raise no. 2, Nov 2019 × Investors in this round 3 investors had bought by the notice of Aug 17, 2020: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Akihiro Ko · Executive Officer, Director Maiko Katadae · Director Minoru Ko · Director Naonori Kurokawa · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Akihiro Ko, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Aug 17, 2020. Read the notice at the SEC .
equity SEC Jun 2018 $4 M No. 1 $2 to $10 million 1
Elixirgen Therapeutics, Inc.: Raise no. 1, Jun 2018 × Investors in this round 1 investor had bought by the notice of Jun 25, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Akihiro Ko · Executive Officer, Director Minoru S.H. Ko · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Akihiro Ko, Chief executive officer. Source: SEC Form D, newest notice filed Jun 25, 2018. Read the notice at the SEC .
equity SEC